Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns run through Certara's acquisitions — what it looks for, how it pays, and how it folds in what it buys.
9 acquisitions — each with the deal value, financing structure, target revenue, and executive commentary where disclosed.
BaseCase is a SaaS company serving the life sciences industry, providing tools for building interactive value-communication and market-access materials used by commercial and medical teams. Certara acquired 100% of BaseCase's equity, adding cloud-based content and value-messaging capability to its market-access and evidence offering. The $25.3 million purchase price was funded with $25.0 million of additional term-loan proceeds plus cash on hand.
Analytica Laser is a consultancy specializing in real-world evidence and health-economics outcomes research, value-and-access strategy, cost and comparative-effectiveness modeling, and the collection and analysis of real-world data for market and payer communications. Certara acquired 100% of the equity, strengthening its regulatory-science and market-access services. The $40.0 million purchase price was funded with $40.0 million of additional term-loan proceeds plus cash on hand.
Pinnacle 21 is a provider of SaaS solutions for clinical-data fitness, regulatory compliance and submission readiness; its software validates compliance with CDISC data standards and is used by the U.S. FDA and Japan's PMDA to review the quality of regulatory submissions, as well as by 22 of the top 25 biopharma companies by R&D spend. Certara acquired 100% of Pinnacle 21 through a merger for total consideration of $339.1 million, comprising roughly $249.1 million cash paid to sellers, $17.2 million cash to others and escrow, and 2,239,717 unregistered shares of Certara common stock (valued at about $72.8 million). It was Certara's largest disclosed acquisition and the anchor of its regulatory data-standardization offering.
With Pinnacle 21's software for high-quality clinical data standardization, we can together provide a broader portfolio of industry-leading software and technology-driven services to our customers worldwide. This transaction amplifies our capabilities to inform critical decisions that further de-risk and expedite the drug development process.William F. Feehery — Ph.D., CEO, Certara
Certara's global footprint and focus on growth fast-forward Pinnacle 21's journey for continued success. I look forward to expanding our technology capabilities together to advance life-saving therapies to patients.Max Kanevsky — Founder and CEO, Pinnacle 21
Integrated Nonclinical Development Solutions (INDS) provides the SEND Explorer software together with drug-development consulting. SEND (Standard for Exchange of Nonclinical Data) is a CDISC standard for submitting nonclinical study data to regulators, so the deal extended Certara's regulatory data-standardization footprint into the nonclinical (preclinical) domain. Certara completed the acquisition for total consideration of approximately $8.0 million; the transaction was not significant to its consolidated financial statements.
Vyasa Analytics provides an AI-powered, scalable deep-learning software and analytics platform used to integrate and analyze content across enterprise data by organizations in healthcare and life sciences, higher education, and state and local government. Certara acquired Vyasa for total estimated consideration of $29.3 million, which included a contingent-consideration liability valued at $19.8 million at closing, payable over three years (70% cash / 30% Certara stock) against annual eligible-revenue thresholds, with potential payments ranging from $0 to $60 million. The deal added deep-learning AI capability to Certara's software portfolio.
Through an asset purchase agreement with the University of Washington, Certara acquired the Drug Interaction Database (DIDB) and related products - a curated database of drug-drug interaction data used in clinical pharmacology and regulatory science. Total estimated consideration was approximately $8.34 million. The acquisition deepened the proprietary data underpinning Certara's biosimulation and drug-interaction offerings.
Formedix Limited provides a clinical metadata repository and clinical-trial data-flow automation software, adding metadata management and study-build automation to Certara's data platform. Certara completed the acquisition for total estimated consideration of approximately $41.4 million ($41.389 million), which included contingent consideration tied to eligible-revenue thresholds (potential earn-out up to roughly $9 million).
Applied BioMath (ABM) is an industry leader in model-informed drug discovery and development, using quantitative systems pharmacology (QSP) modeling to help accelerate and de-risk therapeutic research and development. Certara completed the acquisition for total estimated consideration of approximately $36.6 million, including contingent consideration against eligible-revenue thresholds (earn-out potential up to roughly $17.55 million). The deal strengthened Certara's mechanistic/QSP modeling capability across discovery and development.
Chemaxon (Chemaxon Kft.) is a cheminformatics software company whose products handle chemical structure drawing, property prediction, search and analysis, helping research scientists digitize the design-make-test-analyze (DMTA) lifecycle to identify new chemical leads. Certara - which had partnered with Chemaxon for about ten years - acquired 100% of the equity for total cash consideration of $96.4 million ($87.4 million to sellers plus $9.0 million to escrow), funded in part by new term debt. The deal positioned Certara in the drug-discovery biosimulation market at scale, complementing its later-phase development portfolio. Chemaxon was expected to generate more than $20 million of software revenue in 2024.
The combination of Chemaxon and Certara unites two complementary businesses with a shared mission of reducing drug development costs and risks to develop new medicines faster. Together, we can enhance prediction and analytical capabilities in drug discovery by leveraging biosimulation and generative AI.William Feehery — CEO, Certara
Certara and Chemaxon share a common vision of advancing science and innovation in life sciences. Together, we will offer clients the ability to broadly conduct in-silico research to inform better decision-making at every phase of development.Richard Jones — CEO, Chemaxon